Exothera partners with Quantoom and launches DNA business unit

mRNA vaccine DNA

Exothera has partnered with Quantoom Biosciences to gain access to Quantoom’s Nfinity technology, a continuous production platform for RNA. 

The partnership will enable Exothera to be the first CDMO in the world to offer this off-the-shelf process for the continuous production of RNA as a service. Continuous manufacturing of RNA can provide significant advantages in terms of efficiency, productivity, quality control, cost-effectiveness, and scalability.

Exothera will provide the service through a new business unit, Exothera Nucleic Acids, which focuses on accelerating the process development and manufacturing of RNA vaccines and therapeutics.

Exothera said the partnership will allow biotech and pharma companies to simplify RNA vaccine development and accelerate their clinical and commercial timelines. By leveraging the Nfinity technology, Exothera will offer development services, non GMP and GMP manufacturing as well as analytical services to pharma/biotech for mRNA and saRNA therapeutic development.

Exothera looking to grow RNA vaccine market

Thibault Jonckheere, CEO of Exothera, said: “The market potential for RNA therapies continues to grow and expand into new therapeutic areas, but the process of developing a new RNA vaccine or therapeutic is hindered by outdated technology that was never intended to scale for commercialization. We are thrilled to not only announce the launch of our new business unit focused on nucleic acids, but also our strategic collaboration with Quantoom Biosciences.”

“This collaboration enables Exothera to make the highest quality RNA for vaccines and therapeutics with low-risk process development and almost guaranteed product quality from sequence up to mass production in a much shorter time than previously possible.” 

“We’re thrilled by this new partnership which marks a new milestone for Quantoom, added José Castillo, CEO of Quantoom. 

“The advantages of continuous manufacturing for RNA are clear, and we believe this partnership will provide significant benefits to biotech and pharma companies developing RNA vaccines and therapeutics. By combining Exothera’s expertise with our cutting-edge platform, we can simplify the process and accelerate timelines for RNA development and production. We’re excited to see the impact this partnership will have on the industry and ultimately, on patients’ lives.” 

Partnering 2030: The Biotech Perspective 2023

Download Inpart’s latest report revealing the priorities of out-licensers worldwide.

Newsletter Signup - Under Article / In Page

"*" indicates required fields

Subscribe to our newsletter to get the latest biotech news!

This field is for validation purposes and should be left unchanged.

Suggested Articles

Show More